Lonza Group AG stock (CH0013841017): Ex-dividend date set for May 12

Lonza Group AG goes ex-dividend on May 12, 2026, with shareholders of record on May 13 eligible for a payment of 5.138 USD per share.

Lonza Group AG (CH0013841017) is set to trade ex-dividend on May 12, 2026. Shareholders recorded on May 13, 2026, will receive a dividend of 5.138 USD per share, according to moomoo as of May 10, 2026. This payout underscores the company's commitment to returning capital to investors amid its role in the biopharma contract manufacturing space.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group
• Sector/industry: Healthcare / Contract development and manufacturing
• Headquarters/country: Switzerland
• Core markets: Pharmaceuticals, biotechnology
• Key revenue drivers: Small molecules, biologics, cell & gene therapies
• Home exchange/listing venue: SIX Swiss Exchange (LONN)
• Trading currency: CHF

Lonza Group AG: core business model

Lonza Group AG operates as a leading contract development and manufacturing organization (CDMO) in the healthcare sector. The company provides services across the product lifecycle, from early-stage development to commercial-scale production for pharmaceutical and biotech clients, according to Morningstar as of 2026. Its four key segments include small molecules, biologics, cell and gene technologies, and capsules & health ingredients.

The business model relies on long-term supply agreements with major drugmakers, enabling stable revenue streams. Lonza supports customers in research, development, and manufacturing, serving pharma companies, biotechs, academia, and governments. This diversified approach positions it centrally in the global biopharma supply chain.

Main revenue and product drivers for Lonza Group AG

Revenue is primarily driven by biologics and cell & gene segments, which cater to high-growth areas like advanced therapies. Small molecules remain a steady contributor, while capsules target consumer health. In October 2024, Lonza announced automated bioprocessing solutions for stem cell therapy production to enhance scalability, per openPR as of October 2024.

Key drivers include demand for outsourced manufacturing amid capacity constraints in the industry. Lonza's expertise in modular facilities supports rapid scaling for clients' blockbuster drugs and novel modalities, bolstering its revenue visibility through multi-year contracts.

Industry trends and competitive position

The CDMO market is expanding due to rising complexity in drug development and biopharma's shift toward outsourcing. Lonza holds a strong position with its end-to-end capabilities and investments in next-gen tech like continuous manufacturing. Competitors include Thermo Fisher and Catalent, but Lonza's focus on high-value biologics and cell therapies differentiates it.

Why Lonza Group AG matters for US investors

Lonza's exposure to US-based pharma giants like Pfizer and Moderna makes it relevant for American portfolios. Many of its long-term contracts tie to US drug approvals and market launches, linking performance to the world's largest pharma market. Shares trade OTC in the US as LZAGF, offering accessibility.

Conclusion

The upcoming ex-dividend date highlights Lonza Group AG's shareholder returns policy within its robust CDMO framework. Recent innovations in stem cell manufacturing signal ongoing adaptation to industry needs. US investors may track its ties to domestic biopharma leaders for broader exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.